Mental disorders and adherence to antiretroviral treatment in health facilities in Mozambique ============================================================================================= * Flavio M. Mandlate * M. Claire Greene * Luis F. Pereira * Maria Lidia Gouveia * Jair Jesus Mari * Francine Cournos * Cristiane S. Duarte * Maria A. Oquendo * Marcelo Feijó Mello * Milton L. Wainberg ## Abstract **Introduction** Less adherence to antiretroviral treatment (ART) has been found among people suffering from HIV (PWH) with comorbid mental disorders like depression and alcohol use in Mozambique, a Sub-Saharan African country. However, less is explored with regards to other mental disorders. **Methods** This study assessed the association of multiple mental disorders and adherence to ART based on the data from primary/tertiary health care facilities in Maputo and Nampula, Mozambique. We administered a sociodemographic questionnaire, Mini International Neuropsychiatric Interview (MINI) Plus 4.0.0 adapted for use in Mozambique to assess mental conditions, and a 3-item self-report to measure ART adherence. **Results** Out of 1469 participants, 409 were HIV positive (self-report), with an average age of 36.7 years (SD=9.8), and 30.4% were male. The most common mental disorders were major depressive disorder (27.34%) followed by psychosis (22.03%), suicidal ideation/behavior (15.44%), and alcohol-use disorder (8.35%). Higher levels of non-adherence to ART [(Mean Difference=1.19, 95% CI: 1.04, 1.37)] and the likelihood of missing at least one dose in the last 30 days (OR=3.06, 95% CI: 2.00, 4.67) were found in participants with any mental disorder compared to those without a mental disorder. The highest levels of non-adherence were observed among those with drug use disorders and panic disorder. **Conclusions** In Mozambique, PWH with any co-occurring mental conditions had a lower probability of ART adherence. Integrating comprehensive mental health assessment and treatment and ART adherence interventions tailored to PWH with co-occurring mental disorders is necessary to attain optimal ART adherence and reach the UNAIDS ART target. Keywords * Mental disorders * ART adherence * HIV/AIDS treatment * Mozambique ## Introduction The introduction of effective antiretroviral therapy (ART) in 1996 significantly changed the scenario of HIV epidemic in high-income countries (1). Unfortunately, the global effort to include low-income countries in this treatment drive did not succeeded until 2001 (2, 3). Initially, when ART was introduced, 95% adherence to ART was required to achieve maximal viral suppression (4). Consistent adherence to ART with consequent undetectable HIV viral load increases the life expectancy of people with HIV (PWH) (5) and prevents new HIV infections (6). The current UNAIDS 95-95-95 global effort to end the HIV epidemic by 2030 emphasizes that 95% of people with HIV know their status, 95% of those knowing their status have access to treatment, and 95% of those under treatment have suppressed viral load (7). Factors associated with poor adherence to ART in sub-Saharan countries include unavailability of health care services, stigma, and discrimination, mental health problems (e.g., hazardous alcohol use, depression), negligence to take medications, poor understanding of HIV illness, disbelief about HIV and its treatment, poverty, food insecurity, medication side effects, poor patient-provider relationships, and difficulty accessing health services (8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18). Studies in sub-Saharan Africa and other low-income countries have reported that patients with depression, anxiety, and PTSD symptoms during enrollment in HIV care have shown delayed initiation of ART and negligence to care (19). Moreover, an association of anxiety, depression, and alcohol use has been found with poor adherence to HIV-treatment (20, 21, 22, 23, 24), which in turn leads to high mortality and other poor HIV-related outcomes (25, 26, 27, 28, 23, 24, 29, 30, 31, 32). Studies evaluating the prevalence of mental disorders among PWH in Sub-Saharan Africa, the world’s region with the highest prevalence of HIV/AIDS, have reported the high prevalence of depression, hazardous alcohol use, post-traumatic stress disorder, anxiety disorders, psychosis, bipolar disorders, and suicidal ideation (33, 26, 34, 35, 36, 37, 38; 39) among HIV patients. However, data regarding the association of poor adherence to ART and comorbid mental disorders besides depression and hazardous alcohol use among PWH, is inconsistent. Some studies from high-income countries have found no association (4, 40, 41) while others reported that depression, anxiety, bipolar disorder, substance use disorder, and suicidal behavior are associated with poor adherence (42, 27, 28). Noticeably, anxiety was strongly associated with poor adherence to treatment among PWH in six studies from Asia while four from sub-Saharan Africa did not find any association (43). Among patients with HIV and co-morbidities such as bipolar disorder, nonadherence to psychiatric medication may lead to ART non-adherence with poor outcomes for both conditions (44). The assessment of adherence to ART among bipolar patients is difficult to measure depending on the tool used (44, 45). However, few studies have also shown the contradictory data. Wagner et al in Los Angeles (USA), found high rates of adherence to ART among patients with both serious mental illness and HIV infection (46). These findings are not in line with those from low-income countries. This could be because of poor knowledge of illness, lack of recognition of medication benefits, and negligence to take medication. Adrawa et al also showed an association between alcohol use and non-adherence in community-based ART distribution settings in Uganda, with participants attributing forgetfulness as a major cause of nonadherence (47). Available data suggest that addressing mental health problems by early screening and interventions at the time of counseling, testing, ART initiation, and follow-up care may be critical for better outcomes for PWH (48, 49, 50). Mozambique is among countries with highest prevalence rates of HIV viz. 13.2% in 2015 and 12.6% in 2018 among individuals between 15 to 49 years (51, 52). Although various studies have been conducted in Mozambique which reported rates of adherence to ART (53, 54), to the best of our knowledge none have reported association between non-adherence to ART and mental health problems. To promote adherence to ART treatment in low-resource settings, routine screening and treatment for alcohol use disorder (55) and depression (56) are recommended (26; 34). Unfortunately, lay health workers and healthcare professionals who provide HIV/AIDS treatment services often lack the training and skills to identify and treat co-occurring mental disorders in PWH (29). In Mozambique, similar to most of the low- and middle-income countries (LMICs), screening and treatment for mental conditions have not been integrated into HIV care yet. Psychosocial counselors supervised by psychologists are trained to offer ART adherence counseling but not to identify or treat mental disorders (57). Keeping all this in view, in this study we examined demographic and clinical correlates of adherence to ART among PWH attending two primary health care facilities and one general hospital in the Maputo City metropolitan region, and three health centers in Nampula City. Poor adherence to ART was hypothesized among PWH with mental disorders than those without a co-morbid mental illness. To the best of our knowledge, this is the first study to assess, if any association exists between mental disorders in PWH and adherence to antiretroviral treatments in Mozambique. ## Methods ### Participants and procedures Adults from 6 primary and tertiary health care facilities in Mozambique who reported being HIV+ (n=409) were included in this study. Participants were recruited from 2 primary healthcare facilities (health centers) and 1 tertiary facility in Maputo (general hospital) between May 16 and Jun 8, 2018, and from 3 primary healthcare facilities in Nampula between Nov 28 to Dec 13, 2018. These participants were selected from 1469 adults who had been recruited into a cross-sectional validation study conducted to develop a screening tool for multiple mental disorders (58). Patients and those accompanying them were considered eligible for the study, if they were 18 years of age or older, did not display or reported any cognitive impairment, and provided written consent to participate in the study. Participants were assessed in Portuguese using culturally adapted instruments administered by trained research assistants, including demographic questions and a diagnostic interview for mental disorders. All questionnaires and tools used in the study have been either previously validated or translated and adapted using the WHO recommended method (59). Data were collected with tablets using the REDCap electronic data management system. Participants provided written informed consent as approved by the New York State Psychiatric Institute Institutional Review Board (#7479) and the Ethics Council of Eduardo Mondlane University (CIBS FM & HCM/54/2017). ### Measures *Demographic questions* included information regarding age, sex, the reason for attending the hospital (patient, accompanier, or others), marital status, educational level, occupation, and household income. We also recorded information about the study site (Maputo or Nampula) and facility type (primary vs. tertiary care). *Mental Disorders (MD)* were assessed using a previously published structured diagnostic interview, the Brazilian version of the Portuguese language Mini-International Neuropsychiatric Interview (MINI) Plus 4.0.0 adapted for use in Mozambique (60, 61). The following modules were administered and included in the analysis: major depressive disorder, dysthymic disorder, panic disorder, generalized anxiety disorder, post-traumatic stress disorder, somatization disorders, mania, psychotic disorders, alcohol use disorder, drug use disorder, and suicidal instinct. *HIV status and antiretroviral treatment adherence* were self-reported. All participants reported whether they had HIV in the assessment for chronic diseases done in the interview. Participants who were HIV-positive were queried for ART. Participants on ART were further questioned about the duration of ART and how frequently they go to a medical unit to obtain ART medication. Furthermore, they were asked the following three questions about ART adherence from a 3-item self-report measure for medication adherence, which together forms an *ART adherence composite index* ranging from zero to 100, with scores less than 100 indicating some non-adherence (62): 1. In the last 30 days, how many days did you miss at least one dose of ART medication? 2. In the last 30 days, how well did you stick to taking the ART medication in the way you were supposed to? Response options: Very poor, Poor, Reasonable, Good, Very Good, Excellent 3. In the last 30 days, how often did you take your HIV medicine in the way you were supposed to? Response options: Never, Rarely, Sometimes, Habitually, Almost always, Always As recommended in previous research, the ART adherence composite index was calculated by linearly transforming responses for the three adherence items to a 0-100 scale with zero representing worst adherence and 100 indicating best adherence (62). ### Statistical Analysis Bivariate associations were calculated between ART adherence and 1) socio-demographics and 2) mental disorders using unadjusted logistic regression models among participants who were HIV+ and responded to the questions about HIV ART adherence (N=395). To control the potential confounders of the association between mental disorders and ART adherence, we reported the adjusted odds ratio and 95% confidence interval controlling for sociodemographic characteristics that were significantly associated with individual indicators of ART adherence (sex, site). Logistic regression model was used to establish the association between any non-adherence (*binary variable*) and specific mental disorders and categories of disorders (common mental disorder, severe mental disorder, moderate/severe suicide risk, and substance use disorder). Among participants who reported any non-adherence based on the composite adherence index, we examined the association between specific mental disorders and categories with the level of non-adherence (*continuous variable ranging from 0-100)* in this subgroup. The reference group for each of these models was PWH participants without any mental disorder comorbidities. ## Results Of the 409 participants who self-reported to be HIV-positive, the analytic sample was restricted to HIV positive participants on ART (n=395, 96.58%). Among these 395 participants, 44.81% met the criteria for at least one mental disorder. The most common mental disorders were: major depressive disorder (27.34%) followed by psychotic disorders (22.03%), any suicidal ideation (15.44%), alcohol use disorder (8.35%), mania (6.84%), generalized anxiety disorder (6.08%), post-traumatic stress disorder (4.05%), panic disorder (3.29%), drug use disorder (1.27%), somatization disorders (0.76%), and dysthymic disorder (0.51%). Most of the PWH participants were recruited from Maputo (73.92%) and in primary healthcare settings (70.89%). The mean age of participants was 36.7 years (SD=9.8). Majority (69.6%) of the participants were females. More than half of the participants were married (58.0%). Most of the participants had less than secondary school education (80.8%), and a mix of occupations and income levels which have been represented in Table 1. Relative to participants who reported complete adherence to ART in the past 30 days, those that were not fully adherent were less likely to be females (OR=0.53, 95% CI: 0.31, 0.90) and less likely to be recruited from Nampula (OR=0.23, 95% CI: 0.14, 0.38). ### ART adherence and mental disorder Most of the participants who were on ART reported taking these medications for more than two years (71.1%) and going to the health center monthly to pick up their medication (60.0%), followed by every three months (30.9%) and irregularly (9.1%) (Table 2). Almost three-quarters of the patients (74.68%) reported some non-adherence on at least one of the three questions that comprised the ART composite adherence index in the past 30 days. The presence of a mental disorder was not found to be associated with how long participants had been on ART or how often they went to the health centers to pick up ART. In the unadjusted models, a significant number of participants with any mental disorder reported non-adherence (79.66%) defined as any missed doses, less than excellent adherence to medication regimen, or not always taking medication as prescribed relative to those without a mental disorder (70.64%; OR=1.62, 95% CI: 1.02, 2.60). When adjusting for sex and site, the association between having a mental disorder and any non-adherence was no longer found to be significant (OR=1.57, 95% CI: 0.96, 2.56). We also assessed the association between ART non-adherence and specific types of mental conditions controlling for site and sex (Table 3). Severe mental disorders, including mania and psychotic disorders, displayed increased odds of non-adherence relative to people without mental disorders. Other mental disorders also displayed a similar trend, but the difference was not statistically significant. We do not report the parameter estimates for dysthymia, somatization, and drug use disorders, given the small number of participants meeting these disorders’ criteria and the limited variation in adherence. Association between ART adherence and specific types of mental disorders was also evaluated. Individuals with any severe mental disorder (OR=2.38, 95% CI: 1.24, 4.56), mania (OR=4.66, 95% CI: 1.03, 21.27), or psychotic disorder (OR=2.33, 95% CI: 1.19, 4.56) displayed greater odds of non-adherence relative to individuals without a mental disorder. Among the 295 participants without perfect adherence, we found lower adherence among those with any mental disorder (Mean Diff=-2.99; 95% CI: -5.80, -0.18), panic disorder (Mean Diff=-13.79, 95% CI: -20.98, -6.60), generalized anxiety disorder (Mean Diff=-4.95, 95% CI: -9.64, -0.27), any severe mental disorder (Mean Diff=-3.87, 95% CI: -7.01, -0.73), psychotic disorder (Mean Diff=-4.39, 95% CI: -7.69, -1.09), and any suicide risk (mean Diff=-4.25, 95% CI: -8.13, -0.37) relative to individuals without any mental disorder (Table 3; Figures 1a-b). ![Figure 1a.](http://medrxiv.org/http://medrxiv.stage.highwire.org/content/medrxiv/early/2022/07/18/2022.07.17.22277384/F1.medium.gif) [Figure 1a.](http://medrxiv.org/content/early/2022/07/18/2022.07.17.22277384/F1) Figure 1a. Distribution in level of medication adherence by mental disorder categories ![Figure 1b.](http://medrxiv.org/http://medrxiv.stage.highwire.org/content/medrxiv/early/2022/07/18/2022.07.17.22277384/F2.medium.gif) [Figure 1b.](http://medrxiv.org/content/early/2022/07/18/2022.07.17.22277384/F2) Figure 1b. Distribution in level of medication adherence by mental disorder diagnoses ## Discussion Our study found that among PWH who were taking ART, almost half (44.81%) of the individuals met the criteria for at least one mental disorder. This finding is consistent with other studies where between 33.4%-50% of PWH were reported to have any comorbid mental disorder (63, 64). Most participants in our sample (75%) reported non-adherence to ART in the last 30 days (see Tab.1), which is consistent with a previous study in Mozambique reporting that 77-83% of PWH were non-adherent to ART (65). As in previous studies, we found that younger age was marginally associated with non-adherence to ART (29, 66, 67). In our study, only severe mental illness, which included mania and psychosis, was associated with low adherence. This association could be explained by poor reality testing, insight and judgment, impulsiveness, and disorganization of behavior and thought process, which may impair patients’ ability to take a medication daily (68, 69). However, as suggested by Bogart et al, the use of specialized programs that include access to care management and mental health treatment for patients with severe mental illness may help to narrow the health disparities in this population. They found that following these measures for PWH, there was no difference in the use of ART among patients with severe mental illness when compared with the group without mental illness (70). In the sub-analysis of participants who did not report complete adherence, several other mental disorders were associated with increased odds of non-adherence. Although four studies from sub-Saharan Africa did not find an association between anxiety and poor adherence in PWH, six studies from Asia did describe a strong association, which is similar to our findings (43). It is possible that taking ART may serve as a reminder of having a chronic and stigmatized illness, with a subsequent increase in anxiety. We did find any association between drug use disorders and poor adherence. On the contrary to previous studies in sub-Saharan Africa, we did not identify any association between alcohol use disorder and ART adherence (71; 72). Given that the level of non-adherence among participants with alcohol use disorder in our sample were among the highest, we anticipated that this null finding may be explained, in part, by the analyses being underpowered. An association between depression and poor adherence has been frequently described in the literature. However, in our sample, MDD was not significantly associated with decreased adherence, like a study from Brazil (73). Of note, our findings showed some discrepancies in the association of poor adherence to ART and comorbid mental disorder, mainly regarding depression with other published data (74; 75; 76; 77; 78), but noticeably, there was an association of depressive symptoms with non-adherence within the past (one) month, although not in the past week. This was in line with a previous study which also did not find any associations between mood and suicidality symptoms and missed doses in the past week or month (77). As in our study, two cross-sectional studies did not find a statistically significant association between schizophrenia/psychotic disorder and ART adherence, using a self-report measure ACTG (Adult AIDS Clinical Trials Group adherence questionnaire) 3 - days recall and EDMs (electronic drug monitors) to evaluate adherence to ART (80). The Mozambique Ministry of Health has been implementing task-shifting in their mental health system of care since 1996 by training mid-level mental health specialists supervised by psychiatrists or psychologists in district-level clinics (81; 82). Almost 300 psychiatric technicians have been trained to provide mental health care in primary healthcare facilities throughout urban areas of the country. But 70% of the population lives in rural areas, with limited coverage by mental health professionals, with only one psychiatric technician available per district. It’s therefore challenging to scale up comprehensive mental health services integrated into primary care in rural areas (82, 83). This study has some limitations. First, this is a cross-sectional study, and biological markers did not confirm HIV status and ART adherence. We cannot make causal inferences about the direction of the observed relationship between ART adherence and mental conditions, nor are we able to rule out sources of information bias (e.g., reporting bias and recall bias which can arise in self-report questionnaires) and misclassification. Second, we did not obtain information about what specific ART regimens participants were taking and specific adherence to each ART prescribed. Treatment regimens may have affected the results as several antiretrovirals - including efavirenz, which is still commonly used in Mozambique - cause neuropsychiatric side effects, including depression, anxiety, suicidal ideation, psychosis, and mania. This study did not capture all potential confounders of the association between mental conditions and ART adherence, including CD4 levels and ART regimen (66). Third, this study recruited a convenience sample of PWH in primary and tertiary healthcare facilities and does not represent Mozambique’s general population. The validation study from where our data was obtained was designed to recruit participants with various mental disorders within primary care, HIV care, and mental health clinics. Thus, our findings regarding the proportion of people with mental disorders should not be considered prevalence rates. Fourth, the number of participants meeting the criteria for some mental disorders in our sample was low, resulting in unstable estimates for some conditions (e.g., drug use disorder, somatization disorders). Given the small sample sizes in subgroups, many of the models may have produced unstable and imprecise estimates. Thus, these analyses should be interpreted as exploratory. Future research with larger sample sizes is needed to evaluate the relationship between these low-prevalence mental conditions and ART adherence. Despite these limitations, this study has several strengths, including using a fully structured diagnostic interview to diagnose most mental disorders resulting in a sample with a breadth of mental conditions and replicating a composite index assessing ART adherence instead of a single-item indicator. Finally, to our knowledge, this is the first study to examine the relationship between ART adherence and its negative association with multiple mental disorders in Mozambique and sub-Saharan Africa, a region with a high burden of HIV/AIDS. ## Conclusions We found that PWH with co-occurring mental disorders were less likely to be optimally adherent to ART in Mozambique and therefore less likely to accomplish the 95-95-95 targets. These findings support the integration of comprehensive mental health screening in HIV care in Mozambique, together with ART adherence interventions tailored to PWH with comorbid mental conditions. Future research should study methods to expand current psychosocial support interventions beyond the more common approaches targeting depression and alcohol use disorders. Our study shows the importance of identifying and treating most mental disorders among PWH as they also negatively impact ART adherence, quality of life, and the 95-95-95 targets. Researchers should consider using valid ART adherence measures and interventions and rigorous, and validated comprehensive mental health assessments (58) with accompanying evidence-based treatments (83) to be implemented through task-shifting approaches integrated within HIV care in Mozambique and throughout the region. ## Supporting information Tables [[supplements/277384_file04.docx]](pending:yes) ## Data Availability All data produced in the present work are contained in the manuscript ## Competing interests Dr. Oquendo receives royalties from the Research Foundation for Mental Hygiene for the Columbia Suicide Severity Rating Scale’s commercial use and owns shares in Mantra, Inc. She serves as an advisor to Alkermes and Fundacion Jimenez Diaz (Madrid). Her family owns stock in Bristol Myers Squibb. The other authors declare no competing interests. ## Authors contributions FM, MCG, LFP drafted the manuscript; MCG did statistical analysis; MLG, JJM, CSD, FC, MFM, MLW reviewed the manuscript; CSD, MAO, MLW designed the protocol. All authors agreed to the final version of the manuscript. ## Authors information MLW and MFM are both co-senior authors ## Funding This study was supported by NIMH grant U19MH113203 and T32MH096724; and Fogarty International Center grant D43TW009675. ## Acknowledgments We thank the Mozambican Ministry of Health, National Directorate of Public Health, Maputo City Health Department, Nampula Province Health Department, and research assistants for facilitating data collection and all study participants for their contribution to this work. ## Footnotes * * Senior co-authors * E-mail addresses of authors: Flavio M. Mandlate:fmachado14{at}gmail.com M. Claire Greene: mg4069{at}cumc.columbia.edu Luis F. Pereira: lg2987{at}cumc.columbia.edu Maria Lidia Gouveia: vovotetchauque{at}gmail.com Jair Jesus Mari: jamari17{at}gmail.com Francine Cournos: fc15{at}cumc.columbia.edu Cristiane S Duarte: Cristiane.Duarte{at}nyspi.columbia.edu Maria A. Oquendo: moquendo{at}pennmedicine.upenn.edu Milton Wainberg: Milton.Wainberg{at}nyspi.columbia.edu Marcelo Feijó Mello: feijomellom{at}me.com ## List of abbreviations ACTG : Adult AIDS Clinical Trials Group adherence questionnaire AIDS : Acquired Immunodeficiency Syndrome ART : Antiretroviral Treatment ARV : Antiretroviral AUD : Alcohol Disorder AUDIT : Alcohol Use Disorder Tool ART : Highly Active Antiretroviral Therapy EDM : electronic drug monitor HIV/AIDS : Human Immunodeficiency Virus/ Acquired Immunodeficiency Syndrome MDD : Major Depressive Disorder MD : Mental Disorder MH : Mental Health MINI : Plus Mini-International Neuropsychiatric Interview Plus 4.0.0 PWH : People Living With Human Immunodeficiency Virus/ Acquired Immunodeficiency Syndrome sSA – Sub-Saharan Africa * Received July 17, 2022. * Revision received July 17, 2022. * Accepted July 18, 2022. * © 2022, Posted by Cold Spring Harbor Laboratory The copyright holder for this pre-print is the author. All rights reserved. The material may not be redistributed, re-used or adapted without the author's permission. ## References 1. 1).Panos G, Samonis G, Alexiou VG, Kavarnou GA, Charatsis G, Falagas ME. Mortality and morbidity of HIV infected patients receiving HAART: a cohort study. Curr HIV Res. 2008;6(3):257–260. doi:10.2174/157016208784324976 [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.2174/157016208784324976&link_type=DOI) [PubMed](http://medrxiv.org/lookup/external-ref?access_num=18473789&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2022%2F07%2F18%2F2022.07.17.22277384.atom) [Web of Science](http://medrxiv.org/lookup/external-ref?access_num=000256616100009&link_type=ISI) 2. 2).Schwartländer B, Grubb I, Perriëns J. The 10-year struggle to provide antiretroviral treatment to people with HIV in the developing world. The Lancet. 2006 Aug 5;368(9534):541–6 3. 3).Ford N, Calmy A, Mills EJ. The first decade of antiretroviral therapy in Africa. Globalization and health. 2011 Dec; 7(1):33. 4. 4).Kim J, Lee E, Park BJ, Bang JH, Lee JY. Adherence to antiretroviral therapy and factors affecting low medication adherence among incident HIV-infected individuals during 2009-2016: A nationwide study. Sci Rep. 2018 Feb 16;8(1):3133. doi: 10.1038/s41598-018-21081-x. PMID: 29453393; PMCID: PMC5816616. [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1038/s41598-018-21081-x&link_type=DOI) [PubMed](http://medrxiv.org/lookup/external-ref?access_num=29453393&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2022%2F07%2F18%2F2022.07.17.22277384.atom) 5. 5).Sabin, C. A., & Lundgren, J. D. The natural history of HIV infection. Current Opinion in HIV and AIDS 2013; 8(4), 311–317. [https://doi.org/10.1097/COH.0b013e328361fa66](https://doi.org/10.1097/COH.0b013e328361fa66) 6. 6).Eisinger RW, Dieffenbach CW, Fauci AS. HIV Viral Load and Transmissibility of HIV Infection: Undetectable Equals Untransmittable. JAMA. 2019; 321(5):451–452. [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1001/jama.2018.21167&link_type=DOI) [PubMed](http://medrxiv.org/lookup/external-ref?access_num=http://www.n&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2022%2F07%2F18%2F2022.07.17.22277384.atom) 7. 7).Joint United Nations Programme on HIV/AIDS (UNAIDS). AIDS by the numbers. Jc2571/1/E, 2015. Retrieved from [http://search.unaids.org](http://search.unaids.org) 8. 8).Bezabhe, W. M., Chalmers, L., Bereznicki, L. R., Peterson, G. M., Bimirew, M. A., & Kassie, D. M. (2014). Barriers and facilitators of adherence to antiretroviral drug therapy and retention in care among adult HIV-positive patients: A qualitative study from Ethiopia. PLoS ONE, 9(5). [https://doi.org/10.1371/journal.pone.0097353](https://doi.org/10.1371/journal.pone.0097353) 9. 9).Bukenya D, Mayanja BN, Nakamanya S, Muhumuza R, Seeley J. What causes non-adherence among some individuals on long term antiretroviral therapy? Experiences of individuals with poor viral suppression in Uganda. AIDS Res Ther. 2019 Jan 21;16(1):2. doi: 10.1186/s12981-018-0214-y. PMID: 30665440; PMCID: PMC6340167. [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1186/s12981-018-0214-y&link_type=DOI) [PubMed](http://medrxiv.org/lookup/external-ref?access_num=30665440&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2022%2F07%2F18%2F2022.07.17.22277384.atom) 10. 10).Moucheraud, C., Stern, A. F., Ahearn, C., Ismail, A., Nsubuga-Nyombi, T., Ngonyani, M. M., … Ssensamba, J. (2019). Barriers to HIV treatment adherence: A qualitative study of discrepancies between perceptions of patients and health providers in Tanzania and Uganda. AIDS Patient Care and STDs, 33(9), 406–413. [https://doi.org/10.1089/apc.2019.0053](https://doi.org/10.1089/apc.2019.0053) [PubMed](http://medrxiv.org/lookup/external-ref?access_num=http://www.n&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2022%2F07%2F18%2F2022.07.17.22277384.atom) 11. 11).Suleiman IA, Momo A. Adherence to antiretroviral therapy and its determinants among persons living with HIV/AIDS in Bayelsa state, Nigeria. Pharm Pract (Granada). 2016 Jan-Mar;14(1):631. doi: 10.18549/PharmPract.2016.01.631. Epub 2016 Mar 15. PMID: 27011771; PMCID: PMC4800010. [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.18549/PharmPract.2016.01.631&link_type=DOI) [PubMed](http://medrxiv.org/lookup/external-ref?access_num=27011771&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2022%2F07%2F18%2F2022.07.17.22277384.atom) 12. 12).Croome, N., Ahluwalia, M., Hughes, L. D., & Abas, M. (2017). Patient-reported barriers and facilitators to antiretroviral adherence in sub-Saharan Africa. AIDS, 31(7), 995–1007. [https://doi.org/10.1097/QAD.0000000000001416](https://doi.org/10.1097/QAD.0000000000001416) [PubMed](http://medrxiv.org/lookup/external-ref?access_num=http://www.n&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2022%2F07%2F18%2F2022.07.17.22277384.atom) 13. 13).Anyaike C, Atoyebi OA, Musa OI, Bolarinwa OA, Durowade KA, Ogundiran A, Babatunde OA. Adherence to combined Antiretroviral therapy (cART) among people living with HIV/AIDS in a Tertiary Hospital in Ilorin, Nigeria. Pan Afr Med J. 2019 Jan 7;32:p10. doi: 10.11604/pamj.2019.32.10.7508. PMID: 31080546; PMCID: PMC6497984. [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.11604/pamj.2019.32.10.7508&link_type=DOI) [PubMed](http://medrxiv.org/lookup/external-ref?access_num=31080546&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2022%2F07%2F18%2F2022.07.17.22277384.atom) 14. 14).Genberg BL, Lee Y, Rogers WH, Wilson IB. Four types of barriers to adherence of antiretroviral therapy are associated with decreased adherence over time. AIDS Behav. 2015 Jan;19(1):85–92. doi: 10.1007/s10461-014-0775-2. PMID: 24748240; PMCID: PMC4203705. [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1007/s10461-014-0775-2&link_type=DOI) [PubMed](http://medrxiv.org/lookup/external-ref?access_num=http://www.n&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2022%2F07%2F18%2F2022.07.17.22277384.atom) 15. 15).Umeokonkwo CD, Onoka CA, Agu PA, Ossai EN, Balogun MS, Ogbonnaya LU. Retention in care and adherence to HIV and AIDS treatment in Anambra State Nigeria. BMC Infect Dis. 2019 Jul 22;19(1):654. doi: 10.1186/s12879-019-4293-8. PMID: 31331280; PMCID: PMC6647106. [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1186/s12879-019-4293-8&link_type=DOI) [PubMed](http://medrxiv.org/lookup/external-ref?access_num=31331280&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2022%2F07%2F18%2F2022.07.17.22277384.atom) 16. 16).Dawson-Rose C, Gutin SA, Cummings B, Jaiantilal P, Johnson K, Mbofana F. ART Adherence as a Key Component of Prevention With Persons Living With HIV in Mozambique. J Assoc Nurses AIDS Care. 2016 Jan-Feb;27(1):44–56. doi: 10.1016/j.jana.2015.10.001. Epub 2015 Oct 13. PMID: 26552865; PMCID: PMC6097618. [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1016/j.jana.2015.10.001&link_type=DOI) [PubMed](http://medrxiv.org/lookup/external-ref?access_num=26552865&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2022%2F07%2F18%2F2022.07.17.22277384.atom) 17. 17).Green A. HIV in Mozambique: starting, and staying on, treatment. Lancet. 2016 Jan 30;387(10017):420–1. doi: 10.1016/S0140-6736(16)00213-0. PMID: 26869557. [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1016/S0140-6736(16)00213-0&link_type=DOI) [PubMed](http://medrxiv.org/lookup/external-ref?access_num=26869557&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2022%2F07%2F18%2F2022.07.17.22277384.atom) 18. 18).Groh, K., Audet, C. M., Baptista, A., Sidat, M., Vergara, A., Vermund, S. H., & Moon, T. D. (2011). Barriers to antiretroviral therapy adherence in rural Mozambique. BMC Public Health, 11(1), 650. [https://doi.org/10.1186/1471-2458-11-650](https://doi.org/10.1186/1471-2458-11-650) [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1186/1471-2458-11-650&link_type=DOI) [PubMed](http://medrxiv.org/lookup/external-ref?access_num=21846344&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2022%2F07%2F18%2F2022.07.17.22277384.atom) 19. 19).Parcesepe, A. M., Filiatreau, L. M., Ebasone, P. V., Dzudie, A., Pence, B. W., Wainberg, M., … Nash, D. (2021). Mental health and initiation of antiretroviral treatment at enrolment into HIV care in Cameroon under a national “ treat all “ policylJ: a cross-sectional analysis. Journal of the International AIDS Society 2021, 24, 1–6. [https://doi.org/10.1002/jia2.25842](https://doi.org/10.1002/jia2.25842) 20. 20).Nakimuli-Mpungu E, Bass JK, Alexandre P, Mills EJ, Musisi S, Ram M, Katabira E, Nachega JB. Depression, alcohol use and adherence to antiretroviral therapy in sub-Saharan Africa: a systematic review. AIDS Behav. 2012 Nov;16(8):2101–18. doi: 10.1007/s10461-011-0087-8. PMID: 22116638. [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1007/s10461-011-0087-8&link_type=DOI) [PubMed](http://medrxiv.org/lookup/external-ref?access_num=22116638&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2022%2F07%2F18%2F2022.07.17.22277384.atom) 21. 21).Collins, P. Y., Holman, A. R., Freeman, M. C., & Patel, V. What is the relevance of mental health to HIV/AIDS care and treatment programs in developing countries? A systematic review. AIDS (London, England) 2006; 20(12), 1571–82. [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1097/01.aids.0000238402.70379.d4&link_type=DOI) [PubMed](http://medrxiv.org/lookup/external-ref?access_num=16868437&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2022%2F07%2F18%2F2022.07.17.22277384.atom) [Web of Science](http://medrxiv.org/lookup/external-ref?access_num=000239985800001&link_type=ISI) 22. 22).Nel, A & Kagee, A. Common mental health problems and antiretroviral therapy adherence. AIDS Care, 2011 Nov; 23(11):1360–5. [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1080/09540121.2011.565025&link_type=DOI) [PubMed](http://medrxiv.org/lookup/external-ref?access_num=22022846&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2022%2F07%2F18%2F2022.07.17.22277384.atom) 23. 23).Wykowski, J., Kemp, C. G., Velloza, J., Rao, D., & Drain, P. K. (2019). Associations Between Anxiety and Adherence to Antiretroviral Medications in Low - and Middle - Income Countries: A Systematic Review and Meta - analysis. AIDS and Behavior, 23(8), 2059–2071. [https://doi.org/10.1007/s10461-018-02390-8](https://doi.org/10.1007/s10461-018-02390-8) [PubMed](http://medrxiv.org/lookup/external-ref?access_num=http://www.n&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2022%2F07%2F18%2F2022.07.17.22277384.atom) 24. 24).Magidson, J. F., Saal, W., Nel, A., Remmert, J. E., & Kagee, A. (2017). Relationship between depressive symptoms, alcohol use, and antiretroviral therapy adherence among HIV-infected, clinic-attending patients in South Africa. Journal of Health Psychology, 22(11), 1426–1433. [https://doi.org/10.1177/1359105316628743](https://doi.org/10.1177/1359105316628743) 25. 25).Haas, A. D., Ruffieux, Y., van den Heuvel, L. L., Lund, C., Boulle, A., Euvrard, J., … Wainberg, M. L. (2020). Excess mortality associated with mental illness in people living with HIV in Cape Town, South Africa: a cohort study using linked electronic health records. The Lancet Global Health, 8(10), e1326– e1334. [https://doi.org/10.1016/S2214-109X(20)30279-5](https://doi.org/10.1016/S2214-109X(20)30279-5) 26. 26).Ngum, P. A., Fon, P. N., Ngu, R. C., Verla, V. S., & Luma, H. N. Depression Among HIV / AIDS Patients on Highly Active Antiretroviral Therapy in the Southwest Regional Hospitals of CameroonlJ: A Cross-Sectional Study. Neurology and Therapy 2017, 6(1), 103–114. [https://doi.org/10.1007/s40120-017-0065-9](https://doi.org/10.1007/s40120-017-0065-9) 27. 27).Sajatovic M, Levin J, Fuentes-Casiano E, Cassidy KA, Tatsuoka C, Jenkins JH. Illness experience and reasons for nonadherence among individuals with bipolar disorder who are poorly adherent with medication. Compr Psychiatry. 2011 May-Jun;52(3):280–7. doi: 10.1016/j.comppsych.2010.07.002. Epub 2010 Sep 1. PMID: 21497222; PMCID: PMC3140848. [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1016/j.comppsych.2010.07.002&link_type=DOI) [PubMed](http://medrxiv.org/lookup/external-ref?access_num=21497222&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2022%2F07%2F18%2F2022.07.17.22277384.atom) 28. 28).Mellins CA, Havens JF, McDonnell C, Lichtenstein C, Uldall K, Chesney M, Santamaria EK, Bell J. Adherence to antiretroviral medications and medical care in HIV-infected adults diagnosed with mental and substance abuse disorders. AIDS Care. 2009 Feb;21(2):168–77. doi: 10.1080/09540120802001705. PMID: 19229685; PMCID: PMC5584780. [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1080/09540120802001705&link_type=DOI) [PubMed](http://medrxiv.org/lookup/external-ref?access_num=19229685&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2022%2F07%2F18%2F2022.07.17.22277384.atom) 29. 29).Karcher, H., Omondi, A., Odera, J., Kunz, A., & Harms, G. Risk factors for treatment denial and loss to follow-up in an antiretroviral treatment cohort in Kenya. Tropical Medicine and International Health 2007; 12(5), 687–694. [https://doi.org/10.1111/j.1365-3156.2007.01830.x](https://doi.org/10.1111/j.1365-3156.2007.01830.x) 30. 30).Olowookere, S. A., Fatiregun, A. A., Akinyemi, J. O., Bamgboye, A. E., & Osagbemi, G. K. Prevalence and determinants of nonadherence to highly active antiretroviral therapy among people living with HIV / AIDS in Ibadan, Nigeria. J Infect Developing Countries 2008; 2(5), 369–372. 31. 31).Anyaike, C., Atoyebi, O. A., Musa, O. I., Bolarinwa, O. A., Durowade, K. A., Ogundiran, A., & Babatunde, O. A. Adherence to combined Antiretroviral therapy (cART) among people living with HIV/AIDS in a Tertiary Hospital in Ilorin, Nigeria. Pan African Medical Journal 2019; 32(10), 1–12. [https://doi.org/10.11604/pamj.2019.32.10.7508](https://doi.org/10.11604/pamj.2019.32.10.7508) 32. 32).Haas AD, Ruffieux Y, van den Heuvel LL, Lund C, Boulle A, Euvrard J, Orrell C, Prozesky HW, Tiffin N, Lovero KL, Tlali M, Davies MA, Wainberg ML; IeDEA Southern Africa collaboration. Excess mortality associated with mental illness in people living with HIV in Cape Town, South Africa: a cohort study using linked electronic health records. Lancet Glob Health. 2020 Oct;8(10):e1326–e1334. doi: 10.1016/S2214-109X(20)30279-5. PMID: 32971055; PMCID: PMC7582785. [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1016/S2214-109X(20)30279-5&link_type=DOI) [PubMed](http://medrxiv.org/lookup/external-ref?access_num=32971055&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2022%2F07%2F18%2F2022.07.17.22277384.atom) 33. 33).Chibanda D, Cowan F, Gibson L, Weiss HA, Lund C. Prevalence and correlates of probable common mental disorders in a population with high prevalence of HIV in Zimbabwe. BMC Psychiatry. 2016 Feb 29;16:55. doi: 10.1186/s12888-016-0764-2. PMID: 26926690; PMCID: PMC4772683. [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1186/s12888-016-0764-2&link_type=DOI) [PubMed](http://medrxiv.org/lookup/external-ref?access_num=http://www.n&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2022%2F07%2F18%2F2022.07.17.22277384.atom) 34. 34).Nouaman MN, Vinikoor M, Seydi M, Ekouevi DK, Coffie PA, Mulenga L, Tanon A, Egger M, Dabis F, Jaquet A, Wandeler G; IeDEA. High prevalence of binge drinking among people living with HIV in four African countries. J Int AIDS Soc. 2018 Dec;21(12):e25202. doi: 10.1002/jia2.25202. PMID: 30549445; PMCID: PMC6294116. [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1002/jia2.25202&link_type=DOI) [PubMed](http://medrxiv.org/lookup/external-ref?access_num=30549445&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2022%2F07%2F18%2F2022.07.17.22277384.atom) 35. 35).Klis, S., Velding, K., Gidron, Y., & Peterson, K. Posttraumatic stress and depressive symptoms among people living with HIV in the Gambia. AIDS Care 2011, 23(4), 426–435. [https://doi.org/10.1080/09540121.2010.507756](https://doi.org/10.1080/09540121.2010.507756) [PubMed](http://medrxiv.org/lookup/external-ref?access_num=21271395&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2022%2F07%2F18%2F2022.07.17.22277384.atom) 36. 36).Marwick, K. F. M., & Kaaya, S. F. Prevalence of depression and anxiety disorders in HIV-positive outpatients in rural Tanzania. AIDS Care 2010, 22(4), 415?419. [https://doi.org/10.1080/09540120903253981](https://doi.org/10.1080/09540120903253981) [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1080/09540120903253981&link_type=DOI) [PubMed](http://medrxiv.org/lookup/external-ref?access_num=20131127&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2022%2F07%2F18%2F2022.07.17.22277384.atom) 37. 37).Ogundipe OA, Olagunju AT, Adeyemi JD. Suicidal ideation among attendees of a West African HIV clinic. Arch Suicide Res. 2015;19(1):103–16. doi: 10.1080/13811118.2014.915776. PMID: 25058473. [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1080/13811118.2014.915776&link_type=DOI) [PubMed](http://medrxiv.org/lookup/external-ref?access_num=25058473&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2022%2F07%2F18%2F2022.07.17.22277384.atom) 38. 38).Olagunju, A. T., Adeyemi, J. D., Ogundipe, O. A., & Erinfolami, A. R. Factors associated with anxiety disorders among HIV-positive attendees of an HIV clinic in Lagos, Nigeria. International Journal of STD & AIDS 2012, 23, 389–393. 39. 39).Breuer E, Myer L, Struthers H, Joska JA. HIV/AIDS and mental health research in sub-Saharan Africa: a systematic review. Afr J AIDS Res. 2011 Jun;10(2):101–22. doi: 10.2989/16085906.2011.593373. PMID: 25859733. [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.2989/16085906.2011.593373&link_type=DOI) [PubMed](http://medrxiv.org/lookup/external-ref?access_num=25859733&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2022%2F07%2F18%2F2022.07.17.22277384.atom) 40. 40).Rudy, B. J., Murphy, D. A., Harris, D. R., Muenz, L., & Ellen, J. (2009). Patient-Related Risks for Nonadherence to Antiretroviral Therapy among HIV-Infected Youth in the United States: A Study of Prevalence and Interactions. AIDS PATIENT CARE and STDs, 23(3), 185–194. [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1089/apc.2008.0162&link_type=DOI) [PubMed](http://medrxiv.org/lookup/external-ref?access_num=19866536&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2022%2F07%2F18%2F2022.07.17.22277384.atom) [Web of Science](http://medrxiv.org/lookup/external-ref?access_num=000264406400007&link_type=ISI) 41. 41).Applebaum AJ, Richardson MA, Brady SM, Brief DJ, Keane TM. Gender and other psychosocial factors as predictors of adherence to highly active antiretroviral therapy (HAART) in adults with comorbid HIV/AIDS, psychiatric and substance-related disorder. AIDS Behav. 2009 Feb;13(1):60–5. doi: 10.1007/s10461-008-9441-x. Epub 2008 Aug 9. PMID: 18690532. [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1007/s10461-008-9441-x&link_type=DOI) [PubMed](http://medrxiv.org/lookup/external-ref?access_num=18690532&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2022%2F07%2F18%2F2022.07.17.22277384.atom) 42. 42).López, J.D., Shacham, E. & Brown, T. Suicidal Ideation Persists Among Individuals Engaged in HIV Care in the Era of Antiretroviral Therapy. AIDS Behav 22, 800–805 (2018). [https://doi.org/10.1007/s10461-016-1666-5](https://doi.org/10.1007/s10461-016-1666-5) [PubMed](http://medrxiv.org/lookup/external-ref?access_num=http://www.n&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2022%2F07%2F18%2F2022.07.17.22277384.atom) 43. 43).Wykowski, J., Kemp, C. G., Velloza, J., Rao, D., & Drain, P. K. (2019). Associations between Anxiety and Adherence to Antiretroviral Medications in Low- and Middle-Income Countries: A Systematic Review and Meta-analysis. AIDS Behav., 23(8), 2059–2071. [https://doi.org/10.1007/s10461-018-02390-8](https://doi.org/10.1007/s10461-018-02390-8) [PubMed](http://medrxiv.org/lookup/external-ref?access_num=http://www.n&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2022%2F07%2F18%2F2022.07.17.22277384.atom) 44. 44).Badiee, J., Riggs, P. K., Rooney, A. S., Vaida, F., Grant, I., Atkinson, J. H., & Moore, D. J. (2012). Approaches to identifying appropriate medication adherence assessments for HIV infected individuals with comorbid bipolar disorder. AIDS Patient Care and STDs, 26(7), 388–394. [https://doi.org/10.1089/apc.2011.0447](https://doi.org/10.1089/apc.2011.0447) [PubMed](http://medrxiv.org/lookup/external-ref?access_num=22686169&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2022%2F07%2F18%2F2022.07.17.22277384.atom) 45. 45).Levin JB, Aebi ME, Howland M, Barboza M, Eskew L, Tatsuoka C, Cassidy KA, Sajatovic M. The Relationship Between Medication Attitudes and Medication Adherence Behavior in Adults With Bipolar Disorder. J Nerv Ment Dis. 2020 Feb;208(2):87–93. doi: 10.1097/NMD.0000000000001083. PMID: 31929465; PMCID: PMC7316161. [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1097/NMD.0000000000001083&link_type=DOI) [PubMed](http://medrxiv.org/lookup/external-ref?access_num=31929465&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2022%2F07%2F18%2F2022.07.17.22277384.atom) 46. 46).Wagner, G. J., Kanouse, D. E., Koegel, P., & Sullivan, G. (2003). Adherence to HIV antiretrovirals among persons with serious mental illness. AIDS Patient Care and STDs, 17(4), 179–186. [https://doi.org/10.1089/108729103321619782](https://doi.org/10.1089/108729103321619782) [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1089/108729103321619782&link_type=DOI) [PubMed](http://medrxiv.org/lookup/external-ref?access_num=12737641&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2022%2F07%2F18%2F2022.07.17.22277384.atom) 47. 47).Adrawa, N., Alege, J. B., & Izudi, J. (2020). Alcohol consumption increases nonadherence to ART among people living with HIV enrolled to the community-based care model in rural northern Uganda. PLoS ONE, 15(11 November), 1–12. [https://doi.org/10.1371/journal.pone.0242801](https://doi.org/10.1371/journal.pone.0242801) [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1371/journal.pone.0232391&link_type=DOI) [PubMed](http://medrxiv.org/lookup/external-ref?access_num=http://www.n&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2022%2F07%2F18%2F2022.07.17.22277384.atom) 48. 48).Truong, M., Rane, M. S., Govere, S., Galagan, S. R., Moosa, M. Y., Stoep, A. Vander, … Drain, P. K. (2021). Depression and anxiety as barriers to art initiation, retention in care, and treatment outcomes in KwaZulu-Natal, South Africa. EClinicalMedicine, 31, 100621. [https://doi.org/10.1016/j.eclinm.2020.100621](https://doi.org/10.1016/j.eclinm.2020.100621) 49. 49).Caniglia, E. C., Khan, M., Ban, K., & Braithwaite, R. S. (2021). Integrating Screening and Treatment of Unhealthy Alcohol Use and Depression with Screening and Treatment of Anxiety, Pain, and Other Substance Use Among People with HIV and Other High-Risk Persons. AIDS and Behavior, 25(s3), 339–346. [https://doi.org/10.1007/s10461-021-03245-5](https://doi.org/10.1007/s10461-021-03245-5) 50. 50).Uthman, O. A., Magidson, J. F., Safren, S. A., & Nachega, J. B. (2014). Depression and adherence to antiretroviral therapy in low-, middle- and high-income countries: a systematic review and meta-analysis. Curr HIV/AIDS, 11(3), 291–307. [https://doi.org/10.1007/s11904-014-0220-1](https://doi.org/10.1007/s11904-014-0220-1) 51. 51).Ministério da Saúde-MISAU, Instituto Nacional de Estatística - INE, and ICF. Inquérito de Indicadores de Imunização, Malária e HIV/SIDA em Moçambique (IMASIDA) 2015. Maputo/Moçambique: MISAU/Moçambique, INE, and ICF2018. Available at [http://dhsprogram.com/pubs/pdf/AIS12/AIS12.pdf](http://dhsprogram.com/pubs/pdf/AIS12/AIS12.pdf) 52. 52).UNAIDS. Global HIV & AIDS statistics – 2018 fact sheet. [http://www.unaids.org/en/resources/fact-sheet](http://www.unaids.org/en/resources/fact-sheet) [https://www.unaids.org/en/regionscountries/countries/mozambique](https://www.unaids.org/en/regionscountries/countries/mozambique) 53. 53).Lafort Y, Couto A, Sunderbrink U, Hoek R, Shargie E, Zhao J, Viisainen K, Simwaka B. Validity of reported retention in antiretroviral therapy after roll-out to peripheral facilities in Mozambique: Results of a retrospective national cohort analysis. PLoS One. 2018 Jun 21;13(6):e0198916. doi: 10.1371/journal.pone.0198916. PMID: 29927961; PMCID: PMC6013210. [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1371/journal.pone.0198916&link_type=DOI) [PubMed](http://medrxiv.org/lookup/external-ref?access_num=http://www.n&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2022%2F07%2F18%2F2022.07.17.22277384.atom) 54. 54).Palladino C, Briz V, Bellón JM, Bártolo I, Carvalho P, Camacho R, Muñoz-Fernández MÁ, Bastos R, Manuel R, Casanovas J, Taveira N. Predictors of attrition and immunological failure in HIV-1 patients on highly active antiretroviral therapy from different healthcare settings in Mozambique. PLoS One. 2013 Dec 20;8(12):e82718. doi: 10.1371/journal.pone.0082718. PMID: 24376569; PMCID: PMC3869714. [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1371/journal.pone.0082718&link_type=DOI) [PubMed](http://medrxiv.org/lookup/external-ref?access_num=24376569&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2022%2F07%2F18%2F2022.07.17.22277384.atom) 55. 55).Veld DHI’, Pengpid S, Colebunders R, Skaal L, Peltzer K. High-risk alcohol use and associated socio-demographic, health and psychosocial factors in patients with HIV infection in three primary health care clinics in South Africa. Int J STD AIDS. 2017 Jun;28(7):651–659. doi: 10.1177/0956462416660016. Epub 2016 Jul 21. PMID: 27448655. [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1177/0956462416660016&link_type=DOI) [PubMed](http://medrxiv.org/lookup/external-ref?access_num=27448655&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2022%2F07%2F18%2F2022.07.17.22277384.atom) 56. 56).Nakasujja N, Skolasky RL, Musisi S, Allebeck P, Robertson K, Ronald A, Katabira E, Clifford DB, Sacktor N. Depression symptoms and cognitive function among individuals with advanced HIV infection initiating HAART in Uganda. BMC Psychiatry. 2010 Jun 10;10:44. doi: 10.1186/1471-244X-10-44. PMID: 20537129; PMCID: PMC2901316. [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1186/1471-244X-10-44&link_type=DOI) [PubMed](http://medrxiv.org/lookup/external-ref?access_num=20537129&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2022%2F07%2F18%2F2022.07.17.22277384.atom) 57. 57).Ministério da Saúde (MISAU), DireccCão Nacional de AssisteCncia Médica (DNAM), Guião de actividades de Apoio Psicossocial e PrevencCão Positiva (APSS & PP), 2015 58. 58).Lovero KL BC, Khan S, Suleman A, Mabunda D, Feliciano P, dos Santos P, Fumo W, Greene MC, Fiks Salem A, Mootz JJ, Mocumbi MO, Duarte CS, Gouveia L, Oquendo MA, Wall MM, Wainberg ML. Brief Screening Tool for Stepped-Care Management of Mental and Substance Use Disorders. Psych services 2020. Under Review 59. 59).WHO. Process of translation and adaptation of instruments. [https://www.who.int/substance\_abuse/research\_tools/translation/en/](https://www.who.int/substance_abuse/research_tools/translation/en/) 60. 60).Amorim P. Mini International Neuropsychiatric Interview (MINI): Validação de entrevista breve para diagnóstico de transtornos mentais. Braz J Psychiatry. 2000; 22(3):106–115. 61. 61).Sheehan DV, Lecrubier Y, Sheehan KH, Amorim P, Janavs J, Weiller E, Hergueta T, Baker R, Dunbar GC. The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry. 1998;59 Suppl 20:22–33; quiz 34-57. PMID: 9881538. [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1016/S0924-9338(99)80239-9&link_type=DOI) [PubMed](http://medrxiv.org/lookup/external-ref?access_num=9881538&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2022%2F07%2F18%2F2022.07.17.22277384.atom) 62. 62).Wilson IB, Lee Y, Michaud J, Fowler FJ Jr, Rogers WH. Validation of a New Three-Item Self-Report Measure for Medication Adherence. AIDS Behav. 2016 Nov;20(11):2700–2708. doi: 10.1007/s10461-016-1406-x. PMID: 27098408; PMCID: PMC5071118. [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1007/s10461-016-1406-x&link_type=DOI) [PubMed](http://medrxiv.org/lookup/external-ref?access_num=27098408&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2022%2F07%2F18%2F2022.07.17.22277384.atom) 63. 63).Gaynes, B. N., Pence, B. W., Eron, J. J., & Miller, W. C. (2008). Prevalence and comorbidity of psychiatric diagnoses based on reference standard in an HIV+ patient population. Psychosomatic Medicine, 70(4), 505–511. [https://doi.org/10.1097/PSY.0b013e31816aa0cc](https://doi.org/10.1097/PSY.0b013e31816aa0cc) [Abstract/FREE Full Text](http://medrxiv.org/lookup/ijlink/YTozOntzOjQ6InBhdGgiO3M6MTQ6Ii9sb29rdXAvaWpsaW5rIjtzOjU6InF1ZXJ5IjthOjQ6e3M6ODoibGlua1R5cGUiO3M6NDoiQUJTVCI7czoxMToiam91cm5hbENvZGUiO3M6ODoicHN5Y2htZWQiO3M6NToicmVzaWQiO3M6ODoiNzAvNC81MDUiO3M6NDoiYXRvbSI7czo1MDoiL21lZHJ4aXYvZWFybHkvMjAyMi8wNy8xOC8yMDIyLjA3LjE3LjIyMjc3Mzg0LmF0b20iO31zOjg6ImZyYWdtZW50IjtzOjA6IiI7fQ==) 64. 64).Gill, A., Ranasinghe, A. W. I. P., Sumathipala, A., & Fernando, K. A. (2020). Prevalence of mental health conditions amongst people living with human immunodeficiency virus in one of the most deprived localities in England. International Journal of STD and AIDS, 31(7), 619–626. [https://doi.org/10.1177/0956462420904299](https://doi.org/10.1177/0956462420904299) 65. 65).Filimão DBC, Moon TD, Senise JF, Diaz RS, Sidat M, Castelo A. Individual factors associated with time to non-adherence to ART pick-up within HIV care and treatment services in three health facilities of Zambézia Province, Mozambique. PLoS One. 2019 Mar 25;14(3):e0213804. doi: 10.1371/journal.pone.0213804. PMID: 30908522; PMCID: PMC6433271. [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1371/journal.pone.0213804&link_type=DOI) [PubMed](http://medrxiv.org/lookup/external-ref?access_num=30908522&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2022%2F07%2F18%2F2022.07.17.22277384.atom) 66. 66).Charurat M, Oyegunle M, Benjamin R, Habib A, Eze E, Ele P, Ibanga I, Ajayi S, Eng M, Mondal P, Gebi U, Iwu E, Etiebet MA, Abimiku A, Dakum P, Farley J, Blattner W. Patient retention and adherence to antiretrovirals in a large antiretroviral therapy program in Nigeria: a longitudinal analysis for risk factors. PLoS One. 2010 May 11;5(5):e10584. doi: 10.1371/journal.pone.0010584. PMID: 20485670; PMCID: PMC2868044. [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1371/journal.pone.0010584&link_type=DOI) [PubMed](http://medrxiv.org/lookup/external-ref?access_num=20485670&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2022%2F07%2F18%2F2022.07.17.22277384.atom) 67. 67).Mukui IN, Ng’ang’a L, Williamson J, Wamicwe JN, Vakil S, Katana A, Kim AA. Rates and Predictors of Non-Adherence to Antiretroviral Therapy among HIV-Positive Individuals in Kenya: Results from the Second Kenya AIDS Indicator Survey, 2012. PLoS One. 2016 Dec 1;11(12):e0167465. doi: 10.1371/journal.pone.0167465. PMID: 27907114; PMCID: PMC5131960. [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1371/journal.pone.0167465&link_type=DOI) [PubMed](http://medrxiv.org/lookup/external-ref?access_num=27907114&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2022%2F07%2F18%2F2022.07.17.22277384.atom) 68. 68).Nachega JB, Mutamba B, Basangwa D, Nguyen H, Dowdy DW, Mills EJ, Katabira E, Nakimuli-Mpungu E. Severe mental illness at ART initiation is associated with worse retention in care among HIV-infected Ugandan adults. Trop Med Int Health. 2013 Jan;18(1):53–7. doi: 10.1111/tmi.12019. Epub 2012 Nov 8. PMID: 23136882. [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1111/tmi.12019&link_type=DOI) [PubMed](http://medrxiv.org/lookup/external-ref?access_num=23136882&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2022%2F07%2F18%2F2022.07.17.22277384.atom) 69. 69).Sajatovic, M., Levina, J., Fuentes-Casianoa, E., Cassidy, K. A., Tatsuoka, C., & Jenkins, J. H. Illness experience and reasons for nonadherence among individuals with bipolar disorder who are poorly adherent with medication. Compr Psychiatry 2011; 52(3), 280–287. [https://doi.org/10.1016/j.comppsych.2010.07.002](https://doi.org/10.1016/j.comppsych.2010.07.002) [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1016/j.comppsych.2010.07.002&link_type=DOI) [PubMed](http://medrxiv.org/lookup/external-ref?access_num=21497222&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2022%2F07%2F18%2F2022.07.17.22277384.atom) 70. 70).Bogart LM, Fremont AM, Young AS, Pantoja P, Chinman M, Morton S, Koegel P, Sullivan G, Kanouse DE. Patterns of HIV care for patients with serious mental illness. AIDS Patient Care STDS. 2006 Mar;20(3):175–82. doi: 10.1089/apc.2006.20.175. PMID: 16548714.) [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1089/apc.2006.20.175&link_type=DOI) [PubMed](http://medrxiv.org/lookup/external-ref?access_num=16548714&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2022%2F07%2F18%2F2022.07.17.22277384.atom) 71. 71).Velloza J, Kemp CG, Aunon FM, Ramaiya MK, Creegan E, Simoni JM. Alcohol Use and Antiretroviral Therapy Non-Adherence Among Adults Living with HIV/AIDS in Sub-Saharan Africa: A Systematic Review and Meta-Analysis. AIDS Behav. 2020 Jun;24(6):1727–1742. doi: 10.1007/s10461-019-02716-0. PMID: 31673913; PMCID: PMC7190427. [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1007/s10461-019-02716-0&link_type=DOI) [PubMed](http://medrxiv.org/lookup/external-ref?access_num=31673913&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2022%2F07%2F18%2F2022.07.17.22277384.atom) 72. 72).Chibanda, D., Benjamin, L., Weiss, H. A., & Abas, M. Mental, Neurological, and Substance Use Disorders in People Living With HIV/AIDS in Low- and Middle-Income Countries. J Acquir Immune Defic Syndr 2014;67(1), S54–S67. 73. 73).Campos, L. N., Guimarães, M. D. C., & Remien, R. H. (2010). Anxiety and depression symptoms as risk factors for non-adherence to antiretroviral therapy in Brazil. AIDS and Behavior, 14(2), 289–299. [https://doi.org/10.1007/s10461-008-9435-8](https://doi.org/10.1007/s10461-008-9435-8) [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1007/s10461-008-9435-8&link_type=DOI) [PubMed](http://medrxiv.org/lookup/external-ref?access_num=18648925&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2022%2F07%2F18%2F2022.07.17.22277384.atom) 74. 74).Gonzalez, J. S., Batchelder, A. W., Psaros, C., & Safren, S. A. (2011). Depression and HIV/AIDS treatment nonadherence: A review and meta-analysis. Journal of Acquired Immune Deficiency Syndromes, 58(2), 181–187. [https://doi.org/10.1097/QAI.0B013E31822D490A](https://doi.org/10.1097/QAI.0B013E31822D490A) [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1097/QAI.0b013e31822d490a&link_type=DOI) [PubMed](http://medrxiv.org/lookup/external-ref?access_num=21857529&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2022%2F07%2F18%2F2022.07.17.22277384.atom) 75. 75).Been, S. K., Schadé, A., Bassant, N., Kastelijns, M., Pogány, K., & Verbon, A. (2019). Anxiety, depression and treatment adherence among HIV-infected migrants. AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV, 31(8), 979–987. [https://doi.org/10.1080/09540121.2019.1601676](https://doi.org/10.1080/09540121.2019.1601676) 76. 76).Uthman, O. A., Magidson, J. F., Safren, S. A., & Nachega, J. B. (2014). Depression and adherence to antiretroviral therapy in low-, middle- and high-income countries: a systematic review and meta-analysis. Curr HIV/AIDS, 11(3), 291–307. [https://doi.org/10.1007/s11904-014-0220-1.Depression](https://doi.org/10.1007/s11904-014-0220-1.Depression) 77. 77).Adejumo, O., Oladeji, B., Akpa, O., Malee, K., Baiyewu, O., Ogunniyi, A., … Taiwo, B. (2016). Psychiatric Disorders and adherence to antiretroviral therapy among a population of HIV-infected adults in Nigeria Olurotimi. Int J STD AIDS, 27(11), 938–949. [https://doi.org/10.1177/0956462415600582.Psychiatric](https://doi.org/10.1177/0956462415600582.Psychiatric) [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1177/0956462415600582&link_type=DOI) [PubMed](http://medrxiv.org/lookup/external-ref?access_num=26384949&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2022%2F07%2F18%2F2022.07.17.22277384.atom) 78. 78).Marinda E, Zungu N, Chikovore J, Mthembu J, Magampa M, Mathentamo Q, Nwosu CO, Maoba P, Ramlagan S, Zuma K, Moyo S, Simbayi L. Association Between ART Adherence and Mental Health: Results from a National HIV Sero-Behavioural Survey in South Africa. AIDS Behav. 2022 May;26(5):1517–1529. doi: 10.1007/s10461-021-03505-4. Epub 2021 Oct 23. PMID: 34686946. [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1007/s10461-021-03505-4&link_type=DOI) [PubMed](http://medrxiv.org/lookup/external-ref?access_num=34686946&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2022%2F07%2F18%2F2022.07.17.22277384.atom) 79. 80).Springer, S.A., Dushaj, A. & Azar, M.M. The Impact of DSM-IV Mental Disorders on Adherence to Combination Antiretroviral Therapy Among Adult Persons Living with HIV/AIDS: A Systematic Review. AIDS Behav 16, 2119–2143 (2012). [https://doi.org/10.1007/s10461-012-0212-3](https://doi.org/10.1007/s10461-012-0212-3) [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1007/s10461-012-0212-3&link_type=DOI) [PubMed](http://medrxiv.org/lookup/external-ref?access_num=22644066&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2022%2F07%2F18%2F2022.07.17.22277384.atom) [Web of Science](http://medrxiv.org/lookup/external-ref?access_num=000310316200003&link_type=ISI) 80. 81).Wainberg ML, Lovero KL, Duarte CS, Fiks Salem A, Mello M, Bezuidenhout C, Mootz J, Feliciano P, Suleman A, Fortunato Dos Santos P, Weissman MM, Cournos F, Marques AH, Fumo W, Mabunda D, Alves-Bradford JE, Mello M, Mari JJ, Ngwepe P, Cidav Z, Mocumbi AO, Medina-Marino A, Wall M, Gouveia L, Oquendo MA. Partnerships in Research to Implement and Disseminate Sustainable and Scalable Evidence-Based Practices (PRIDE) in Mozambique. Psychiatr Serv. 2020 Dec 18:appips202000090. doi: 10.1176/appi.ps.202000090. Epub ahead of print. PMID: 33334157. [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1176/appi.ps.202000090&link_type=DOI) [PubMed](http://medrxiv.org/lookup/external-ref?access_num=33334157&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2022%2F07%2F18%2F2022.07.17.22277384.atom) 81. 82).Dos Santos PF, Wainberg ML, Caldas-de-Almeida JM, Saraceno B, Mari Jde J. Overview of the mental health system in Mozambique: addressing the treatment gap with a task-shifting strategy in primary care. Int J Ment Health Syst. 2016 Jan 4;10:1. doi: 10.1186/s13033-015-0032-8. PMID: 26734070; PMCID: PMC4700645. [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1186/s13033-015-0032-8&link_type=DOI) [PubMed](http://medrxiv.org/lookup/external-ref?access_num=http://www.n&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2022%2F07%2F18%2F2022.07.17.22277384.atom) 82. 83).Wainberg ML, Gouveia ML, Stockton MA, Feliciano P, Suleman A, Mootz JJ, Mello M, Fiks Salem A, Greene MC, Bezuidenhout C, Ngwepe P, Lovero KL, Fortunato Dos Santos P, Schriger SH, Mandell DS, Mulumba R, Neves Anube A, Mabunda D, Mandlate F, Cournos F, Alves-Bradford JM, Nicholson T, Kann B, Fumo W, Duarte CS, de Jesus Mari J, Mello MF, Mocumbi AO, Oquendo MA, Weissman MM. Technology and implementation science to forge the future of evidence-based psychotherapies: the PRIDE scale-up study. Evid Based Ment Health. 2021 Feb;24(1):19–24. doi: 10.1136/ebmental-2020-300199. Epub 2020 Nov 11. PMID: 33177149; PMCID: PMC8025148 [Abstract/FREE Full Text](http://medrxiv.org/lookup/ijlink/YTozOntzOjQ6InBhdGgiO3M6MTQ6Ii9sb29rdXAvaWpsaW5rIjtzOjU6InF1ZXJ5IjthOjQ6e3M6ODoibGlua1R5cGUiO3M6NDoiQUJTVCI7czoxMToiam91cm5hbENvZGUiO3M6ODoiZWJtZW50YWwiO3M6NToicmVzaWQiO3M6NzoiMjQvMS8xOSI7czo0OiJhdG9tIjtzOjUwOiIvbWVkcnhpdi9lYXJseS8yMDIyLzA3LzE4LzIwMjIuMDcuMTcuMjIyNzczODQuYXRvbSI7fXM6ODoiZnJhZ21lbnQiO3M6MDoiIjt9)